Accessibility Statement

Press Releases


Lilly to Participate in Cowen's 44th Annual Health Care Conference

February 20, 2024

Tags |  Financial

INDIANAPOLIS , Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024 . Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time .




Philip Johnson to Retire as Lilly Treasurer

February 9, 2024

Tags |  Corporate

INDIANAPOLIS , Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson , group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity.




Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

February 6, 2024

Tags |  Financial

Revenue in Q4 2023 increased 28%. New Products (i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products (ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included  FDA approval of Zepbound for




Johna Norton to Retire as Lilly Executive Vice President of Global Quality

January 25, 2024

Tags |  Corporate

INDIANAPOLIS , Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton , executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024 . She will continue to serve at full capacity in her




Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

January 23, 2024

Tags |  Corporate

Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss AK-OTOF is a gene therapy being developed for the treatment of sensorineural




Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance

January 23, 2024

Tags |  Financial

INDIANAPOLIS , Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the




Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™

January 4, 2024

Tags |  Corporate

INDIANAPOLIS , Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent




Open Letter Regarding the Use of Mounjaro® (tirzepatide) and Zepbound™ (tirzepatide)

January 4, 2024

Tags |  Corporate General

Open Letter Regarding Use of Lilly’s FDA-Approved Tirzepatide Medicines Lilly is committed to meeting the needs of people affected by diabetes and obesity with treatment options that change the way healthcare providers can treat these diseases and offer breakthroughs for patients.




Lilly to Participate in J.P. Morgan Healthcare Conference

January 2, 2024

Tags |  Financial

INDIANAPOLIS , Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference , Jan. 8-11, 2024 . David A. Ricks, Lilly 's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time .




Lilly Completes Acquisition of POINT Biopharma

December 27, 2023

Tags |  Corporate

INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in